UroGen Pharma (URGN) announced that adult patients living with recurrent low-grade intermediate-risk non-muscle invasive ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins ...

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Urogen Pharma (URGN – Research Report), retaining the price target of $54.00. Ram Selvaraju has given his Buy rating due to a ...

PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...

The latest price target for UroGen Pharma (NASDAQ:URGN) was reported by HC Wainwright & Co. on October 27, 2025. The analyst firm set a price target for $40.00 expecting URGN to rise to within 12 ...

As of May 11, 2023, the average one-year price target for UroGen Pharma is 23.05. The forecasts range from a low of 10.10 to a high of $49.35. The average price target represents an increase of 91.30% ...

We recently compiled a list of the 10 Worst ADR Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where UroGen Pharma (NASDAQ:URGN) stands against the other ADR ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...

UroGen Pharma Ltd.(NASDAQ:URGN) shares traded lower Wednesday after the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration voted against the benefit/risk of UGN-102 ...